An open label study to evaluate the safety and effect on sustained virological response of Pegasys [peginterferon-alfa-2a] plus ribavirin in patients with hemophilia A and chronic hepatitis C
Phase of Trial: Phase IV
Latest Information Update: 23 May 2013
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 26 Mar 2008 The expected completion date for this trial is now 1 Jul 2006.
- 30 May 2007 New trial record.